Compare Ascendis Pharma A/S (ASND) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while YieldMax NVDA Option Income Strategy ETF trades at $12.66. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ASND | NVDY | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $17.96 |
52-Week Low | $163.32 | $12.03 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.75, up 2.66% today, amid a bearish technical signal. The fund generates weekly dividends from selling options on NVIDIA stock, with recent payouts ranging from $0.10 to $0.21. Key support sits at $12, resistance at $13, while RSI readings are neutral but ADX indicates a strong downtrend. News highlights focus on the trade-off between income and missing NVIDIA's upside potential.
Outlook hinges on NVIDIA's volatility sustaining option premiums, offering high yield but capped gains. Risks include underperformance if NVIDIA rallies sharply and reliance on options strategy execution. The fund appeals to income-focused investors willing to sacrifice growth for distributions, with sentiment mixed due to opportunity cost concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
